May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Long-Term Intraocular Pressure (IOP) Fluctuation - An Alternative Parameter for Assessing IOP Control in Clinical Trials
Author Affiliations & Notes
  • L.-J. Hwang
    Pfizer Inc., New York, New York
    Clinical R & D,
  • R. Varma
    USC Keck School of Medicine, Los Angeles, California
  • J. W. Grunden
    Pfizer Inc., New York, New York
    Worldwide Medical Organization,
  • Footnotes
    Commercial Relationships L. Hwang, Pfizer Inc, E; R. Varma, Alcon, C; Allergan, C; Pfizer Inc, R; Pfizer Inc, C; Alcon, R; Allergan, R; J.W. Grunden, Pfizer Inc, E.
  • Footnotes
    Support Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1264. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.-J. Hwang, R. Varma, J. W. Grunden; Long-Term Intraocular Pressure (IOP) Fluctuation - An Alternative Parameter for Assessing IOP Control in Clinical Trials. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1264. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: Mean diurnal IOP is generally used as the primary measure of IOP control. However, recent evidence suggests long-term IOP fluctuation may be important in the development of optic nerve damage. We evaluated whether long-term IOP fluctuation provides additional information on IOP control from data collected in the XLT (Xalatan Lumigan Travatan) study.

Methods:: The XLT study was a masked-evaluator, randomized, parallel-group comparison of the efficacy of X, L, and T after 12 weeks of treatment in patients with open-angle glaucoma or ocular hypertension (OHT). Pre-treatment IOP was measured once at screening (-4 weeks), once (-2 weeks) during a 4-week washout period as a safety check, and 4 times (8:00 AM, 12 noon, 4:00 PM, 8:00 PM) at baseline. Post-treatment IOP was assessed once at Week 2 and 4 times (time points as above) at Weeks 6 and 12. IOP fluctuation was defined as the IOP range (Highest - Lowest IOPs) during the specified period (pre- or post-treatment).

Results:: Included in the analyses were 410 patients (X: 136, L: 136, T: 138). Reductions in mean IOP were similar among the treatment groups.1 Pre-treatment mean IOP fluctuations were similar across the groups (range, 7.5-7.8 mmHg). Treatment with X, L, and T resulted in significant within-treatment-group reductions in mean IOP fluctuation during 12 weeks (X: -2.69, L: -2.41, T: -1.90 mmHg; p< 0.01). When IOP fluctuation was dichotomized as ≤6 (low) or > 6 mmHg (high), percentages of patients with high IOP fluctuation in each group were comparable before treatment (63%-64%). After 12 weeks of treatment, percentages of patients with high fluctuation were reduced to 21%, 28%, and 36% in the X, L, and T groups, respectively; the overall comparison among groups was significant (p=0.016) as was the pair-wise comparison between X and T (p=0.005).

Conclusions:: In the XLT study, there were no statistically significant differences at Week 12 between therapies in mean IOP reductions at 8:00 AM (peak) or 8:00 PM (trough). However, when assessing long-term IOP fluctuation, our analysis noted differences between treatment groups. Thus, determining only mean IOP reduction may not provide a complete assessment of IOP control. IOP fluctuation may be another useful method of evaluating IOP control particularly in trials on patients with glaucoma or OHT.1. Parrish RK et al. Am J Ophthalmol 2003;135:688-703.

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.